Expression and regulation of steroid 5α-reductase 2 in prostate disease

R. I. Silver, E. L. Wiley, D. L. Davis, A. E. Thigpen, D. W. Russell, J. D. McConnell

Research output: Contribution to journalArticle

74 Scopus citations

Abstract

The androgen dihydrotestosterone is synthesized by the enzyme steroid 5α- reductase, and it is required for growth and development of the prostate. We used immunohistochemistry to examine the expression of the type 2 isozyme of 5α-reductase in benign prostatic hyperplasia and prostate cancer. The type 2 isozyme is highly expressed within stromal cells in both disease states. No type 2 isozyme is detectable in a lymph node metastasis. Immunoblotting studies show that androgen ablation therapies substantially decrease isozyme expression in the epididymis but have a lesser effect on expression in the prostate. Finasteride therapy (2 weeks to 3 years) did not abolish expression of the prostatic type 2 isozyme nor did this drug treatment induce expression of the type 1 isozyme.

Original languageEnglish (US)
Pages (from-to)433-437
Number of pages5
JournalJournal of Urology
Volume152
Issue number2
DOIs
StatePublished - Jan 1 1994

Keywords

  • androgens
  • antiandrogens
  • dihydrotestosterone
  • prostatic hypertrophy
  • prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Expression and regulation of steroid 5α-reductase 2 in prostate disease'. Together they form a unique fingerprint.

Cite this